Molhoek JE, de Groot PG, Urbanus RT (July 2018). "The Lupus Anticoagulant Paradox". Semin Thromb Hemost. 44 (5): 445–452. doi:10.1055/s-0037-1606190. PMID28898901.
Htet, S.; Hayes, L.; Leung, T. (2015). "Strong lupus anticoagulant (LA) as a cause for prolonged prothrombin time (PT), activated partial thromboplastin time (APTT) and abnormally low intrinsic factor (IF) levels". Pathology. 47: S90. doi:10.1097/01.PAT.0000461585.89264.ae. ISSN0031-3025. S2CID74865864.
Efthymiou M, Bertolaccini ML, Cohen H (February 2024). "Viewpoint: Lupus anticoagulant detection and interpretation in antiphospholipid syndrome". Rheumatology (Oxford). 63 (SI): SI54–SI63. doi:10.1093/rheumatology/kead623. PMID38320587.
Denis-Magdelaine, A.; Flahault, A.; Verdy, E. (1995). "Sensitivity of Sixteen APTT Reagents for the Presence of Lupus Anticoagulants". Pathophysiology of Haemostasis and Thrombosis. 25 (3): 98–105. doi:10.1159/000217148. ISSN1424-8832. PMID7607585.
Triplett DA, Barna LK, Unger GA (1993). "A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification". Thromb Haemost. 70 (5): 787–93. doi:10.1055/s-0038-1649671. PMID8128436. S2CID35046350.
Devreese KM, de Groot PG, de Laat B, Erkan D, Favaloro EJ, Mackie I, Martinuzzo M, Ortel TL, Pengo V, Rand JH, Tripodi A, Wahl D, Cohen H (November 2020). "Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation". J Thromb Haemost. 18 (11): 2828–39. doi:10.1111/jth.15047. PMID33462974.
Keeling D, Mackie I, Moore GW, Greer IA, Greaves M (April 2012). "Guidelines on the investigation and management of antiphospholipid syndrome". Br J Haematol. 157 (1): 47–58. doi:10.1111/j.1365-2141.2012.09037.x. PMID22313321.
Favaloro EJ (January 2020). "Coagulation mixing studies: Utility, algorithmic strategies and limitations for lupus anticoagulant testing or follow up of abnormal coagulation tests". Am J Hematol. 95 (1): 117–128. doi:10.1002/ajh.25669. PMID31674066.
"Lupus Anticoagulant Testing". Lab Tests Online. 6 December 2019. Last reviewed on August 22, 2018. This article was last modified on December 6, 2019.
Molhoek JE, de Groot PG, Urbanus RT (July 2018). "The Lupus Anticoagulant Paradox". Semin Thromb Hemost. 44 (5): 445–452. doi:10.1055/s-0037-1606190. PMID28898901.
Efthymiou M, Bertolaccini ML, Cohen H (February 2024). "Viewpoint: Lupus anticoagulant detection and interpretation in antiphospholipid syndrome". Rheumatology (Oxford). 63 (SI): SI54–SI63. doi:10.1093/rheumatology/kead623. PMID38320587.
Denis-Magdelaine, A.; Flahault, A.; Verdy, E. (1995). "Sensitivity of Sixteen APTT Reagents for the Presence of Lupus Anticoagulants". Pathophysiology of Haemostasis and Thrombosis. 25 (3): 98–105. doi:10.1159/000217148. ISSN1424-8832. PMID7607585.
Triplett DA, Barna LK, Unger GA (1993). "A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification". Thromb Haemost. 70 (5): 787–93. doi:10.1055/s-0038-1649671. PMID8128436. S2CID35046350.
Devreese KM, de Groot PG, de Laat B, Erkan D, Favaloro EJ, Mackie I, Martinuzzo M, Ortel TL, Pengo V, Rand JH, Tripodi A, Wahl D, Cohen H (November 2020). "Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation". J Thromb Haemost. 18 (11): 2828–39. doi:10.1111/jth.15047. PMID33462974.
Keeling D, Mackie I, Moore GW, Greer IA, Greaves M (April 2012). "Guidelines on the investigation and management of antiphospholipid syndrome". Br J Haematol. 157 (1): 47–58. doi:10.1111/j.1365-2141.2012.09037.x. PMID22313321.
Favaloro EJ (January 2020). "Coagulation mixing studies: Utility, algorithmic strategies and limitations for lupus anticoagulant testing or follow up of abnormal coagulation tests". Am J Hematol. 95 (1): 117–128. doi:10.1002/ajh.25669. PMID31674066.
Viard JP, Amoura Z, Bach JF (1991). "[Anti-beta 2 glycoprotein I antibodies in systemic lupus erythematosus: a marker of thrombosis associated with a circulating anticoagulant]". Comptes Rendus de l'Académie des Sciences, Série III (in French). 313 (13): 607–12. PMID1782567.
Htet, S.; Hayes, L.; Leung, T. (2015). "Strong lupus anticoagulant (LA) as a cause for prolonged prothrombin time (PT), activated partial thromboplastin time (APTT) and abnormally low intrinsic factor (IF) levels". Pathology. 47: S90. doi:10.1097/01.PAT.0000461585.89264.ae. ISSN0031-3025. S2CID74865864.
Triplett DA, Barna LK, Unger GA (1993). "A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification". Thromb Haemost. 70 (5): 787–93. doi:10.1055/s-0038-1649671. PMID8128436. S2CID35046350.
Htet, S.; Hayes, L.; Leung, T. (2015). "Strong lupus anticoagulant (LA) as a cause for prolonged prothrombin time (PT), activated partial thromboplastin time (APTT) and abnormally low intrinsic factor (IF) levels". Pathology. 47: S90. doi:10.1097/01.PAT.0000461585.89264.ae. ISSN0031-3025. S2CID74865864.
Denis-Magdelaine, A.; Flahault, A.; Verdy, E. (1995). "Sensitivity of Sixteen APTT Reagents for the Presence of Lupus Anticoagulants". Pathophysiology of Haemostasis and Thrombosis. 25 (3): 98–105. doi:10.1159/000217148. ISSN1424-8832. PMID7607585.